ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
ProKidney Corp (Nasdaq: PROK), a late clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD), announced its participation in two major healthcare conferences this November. The company will present at the Guggenheim Inaugural Healthcare Innovation Conference in Boston on November 13, 2024, at 10:30am ET, and the Jefferies London Healthcare Conference on November 20, 2024, at 10:00am GMT.
Both presentations will be in a fireside chat format, with live webcasts available through ProKidney's website. Replays will be accessible for 90 days after the events. The management team will also conduct one-on-one meetings with investors during both conferences.
ProKidney Corp (Nasdaq: PROK), una azienda biotech in fase clinica avanzata che sviluppa terapie cellulari per la malattia renale cronica (CKD), ha annunciato la sua partecipazione a due importanti conferenze sanitarie questo novembre. L'azienda presenterà alla Guggenheim Inaugural Healthcare Innovation Conference a Boston il 13 novembre 2024, alle 10:30 ET, e alla Jefferies London Healthcare Conference il 20 novembre 2024, alle 10:00 GMT.
Entrambi i interventi si svolgeranno in formato colloquio informale, con webcast dal vivo disponibili tramite il sito web di ProKidney. Le registrazioni saranno accessibili per 90 giorni dopo gli eventi. Il team dirigenziale condurrà anche incontri individuali con gli investitori durante entrambe le conferenze.
ProKidney Corp (Nasdaq: PROK), una empresa biotecnológica en etapa clínica avanzada que desarrolla terapia celular para la enfermedad renal crónica (ERC), anunció su participación en dos importantes conferencias de salud este noviembre. La compañía presentará en la Guggenheim Inaugural Healthcare Innovation Conference en Boston el 13 de noviembre de 2024, a las 10:30 ET, y en la Jefferies London Healthcare Conference el 20 de noviembre de 2024, a las 10:00 GMT.
Ambas presentaciones se llevarán a cabo en un formato de charla junto a la chimenea, con retransmisiones en vivo disponibles a través del sitio web de ProKidney. Las repeticiones estarán accesibles durante 90 días después de los eventos. El equipo directivo también realizará reuniones uno a uno con inversores durante ambas conferencias.
ProKidney Corp (Nasdaq: PROK)는 만성 신장 질환 (CKD)을 위한 세포 치료제를 개발하고 있는 후기 임상 단계 생명공학 회사로서, 이번 11월에 두 개의 주요 의료 컨퍼런스에 참석할 예정이라고 발표했습니다. 이 회사는 2024년 11월 13일 오전 10:30 ET에 보스턴에서 열리는 구겐하임 제1회 의료 혁신 컨퍼런스와 2024년 11월 20일 오전 10:00 GMT에 열리는 제프리즈 런던 의료 컨퍼런스에서 발표를 진행할 것입니다.
두 발표는 난로 옆 대화 형식으로 진행되며, ProKidney 웹사이트를 통해 실시간 웹캐스트를 이용할 수 있습니다. 이벤트 이후 90일 동안 다시 시청할 수 있는 재방송도 제공될 예정입니다. 경영진 팀은 두 컨퍼런스 기간 동안 투자자와의 일대일 회의도 진행할 것입니다.
ProKidney Corp (Nasdaq: PROK), une entreprise biopharmaceutique en phase clinique avancée développant une thérapie cellulaire pour la maladie rénale chronique (MRC), a annoncé sa participation à deux grandes conférences de santé en novembre. L'entreprise présentera à la Guggenheim Inaugural Healthcare Innovation Conference à Boston le 13 novembre 2024 à 10h30 ET, et à la Jefferies London Healthcare Conference le 20 novembre 2024 à 10h00 GMT.
Les deux présentations se dérouleront sous forme de discussion informelle, avec des webdiffusions en direct accessibles via le site Web de ProKidney. Les rediffusions seront disponibles pendant 90 jours après les événements. L'équipe de direction tiendra également des réunions individuelles avec des investisseurs lors des deux conférences.
ProKidney Corp (Nasdaq: PROK), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das Zelltherapien für chronische Nierenerkrankungen (CKD) entwickelt, gab seine Teilnahme an zwei wichtigen Gesundheitskonferenzen im November bekannt. Das Unternehmen wird am 13. November 2024 um 10:30 Uhr ET auf der Guggenheim Inaugural Healthcare Innovation Conference in Boston und am 20. November 2024 um 10:00 Uhr GMT auf der Jefferies London Healthcare Conference präsentieren.
Beide Präsentationen werden im Format eines informellen Gesprächs stattfinden, wobei Live-Übertragungen über die Website von ProKidney verfügbar sein werden. Die Wiederholungen sind für 90 Tage nach den Veranstaltungen zugänglich. Das Management-Team wird während beider Konferenzen auch persönliche Meetings mit Investoren durchführen.
- None.
- None.
WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in two upcoming healthcare conferences in November.
| Guggenheim Inaugural Healthcare Innovation Conference (Boston) | |
| Date: | Wed, November 13, 2024 |
| Time: | 10:30am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
| Jefferies London Healthcare Conference | |
| Date: | Wed, November 20, 2024 |
| Time: | 10:00am GMT |
| Format: | Fireside Chat |
| Webcast: | Link |
The live webcasts will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of each event, a replay will be available for 90 days.
The ProKidney management team will also host one-on-one meetings during these events. Interested investors should contact their Guggenheim and Jefferies representatives to schedule meetings.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
When is ProKidney (PROK) presenting at the Guggenheim Healthcare Conference in 2024?
What conferences is ProKidney (PROK) attending in November 2024?
How long will ProKidney's (PROK) conference webcasts be available for replay?
What time is ProKidney's (PROK) presentation at the Jefferies London Healthcare Conference?
